scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
P/B ratio for scPharmaceuticals Inc. (SCPH)
P/B ratio as of 2023: 6.49
According to scPharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.49. At the end of 2022 the company had a P/B ratio of -0.90.
P/B ratio history for scPharmaceuticals Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 6.49 |
| 2022 | -0.90 |
| 2021 | -0.72 |
| 2020 | -0.80 |
| 2019 | -0.81 |
| 2018 | -0.72 |
| 2017 | 0.34 |
| 2016 | -4.26 |
| 2015 | -8.66 |